Inclusion Criteria:  Male healthy volunteers, aged between 18 and 65 years of age inclusive, with a body mass index (BMI) within 18-26 kg/m2 (inclusive); Medical history, vital signs, physical examination, 12-lead Electrocardiogram, chest X-ray and abdominal color ultrasound are normal or abnormal with no clinical significance; All variables of clinical laboratory tests are normal or abnormal with no clinical significance; Subjects and partners agree to take effective contraception throughout the study (from screening to 3 months after the end of treatment); Capable of understanding the nature of the study and voluntarily signing the Informed Consent Form.  Exclusion Criteria:  Known allergy to monoclonal antibody drugs or other related drugs, or allergy to excipients of CM326 injection; History of any clinically serious disease or history of circulatory, endocrine, neurological or hematological, immune, psychiatric, and metabolic diseases; History of asthma and allergic reactions; Use of any prescription drugs within 2 weeks prior to dosing, use of traditional Chinese medicine or over-the-counter drugs within 1 week prior to dosing; Received any marketed or investigational biologics within 5 half-lives (if known) or 12 weeks (whichever is longer) prior to dosing, or any investigational non-biologics within 5 half-lives (if known) or 4 weeks (whichever is longer) prior to dosing.